This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HARP Harpoon Therapeutics (HARP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Harpoon Therapeutics Stock (NASDAQ:HARP) 30 days 90 days 365 days Advanced Chart Get Harpoon Therapeutics alerts:Sign Up Key Stats Today's Range$23.01▼$23.0150-Day Range$22.34▼$23.0152-Week Range$3.11▼$23.21VolumeN/AAverage Volume1.52 million shsMarket Capitalization$389.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma. Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential. Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications. Read More Receive HARP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HARP Stock News HeadlinesShould You Count on MRK for Steady Passive Income?June 28, 2025 | msn.comDoes Merck Stock Have Room For Growth?April 29, 2025 | forbes.comAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)Tech Moves: Starbucks names CFO; Avanade bolsters C-suite; Tune Therapeutics gets CEOMarch 4, 2025 | msn.comUmoja Biopharma Announces Appointment of Dr. Luke Walker as Chief Medical OfficerJanuary 27, 2025 | markets.businessinsider.comSA Asks: Which biotechs are most likely to be acquired near-term?January 5, 2025 | msn.comUmoja Biopharma Appoints Scott Myers as Chairman of its Board of DirectorsNovember 21, 2024 | markets.businessinsider.comThe Harpoon Missile: A Great But Obsolete Weapon?October 20, 2024 | msn.comSee More Headlines HARP Stock Analysis - Frequently Asked Questions How were Harpoon Therapeutics' earnings last quarter? Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share for the quarter, missing the consensus estimate of ($4.70) by $0.80. The company had revenue of $4.09 million for the quarter, compared to the consensus estimate of $11.06 million. Harpoon Therapeutics had a negative net margin of 81.68% and a negative trailing twelve-month return on equity of 893.55%. When did Harpoon Therapeutics' stock split? Shares of Harpoon Therapeutics reverse split before market open on Tuesday, September 5th 2023.The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Harpoon Therapeutics IPO? Harpoon Therapeutics (HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers. What other stocks do shareholders of Harpoon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harpoon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings3/27/2023Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:HARP CIK1708493 Webwww.harpoontx.com Phone(650) 443-7400FaxN/AEmployees53Year FoundedN/AProfitability EPS (Trailing Twelve Months)($8.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.73 million Net Margins-81.68% Pretax Margin-81.67% Return on Equity-893.55% Return on Assets-45.98% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$37.34 million Price / Sales10.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.63 per share Price / Book14.12Miscellaneous Outstanding Shares16,932,000Free Float14,054,000Market Cap$389.61 million OptionableOptionable Beta2.11 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:HARP) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harpoon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harpoon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.